Achieve Life Sciences (ACHV) Change in Accured Expenses (2010 - 2026)
Achieve Life Sciences (ACHV) posted Change in Accured Expenses of $261000.0 for Q1 2026, up 151.18% on a QoQ basis from -$510000.0 in Q4 2025, and up 112.65% year-over-year from $122739.6 in Q1 2025.
Achieve Life Sciences (ACHV) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Achieve Life Sciences' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at $261000.0 for Q1 2026.
- Quarterly Change in Accured Expenses rose 112.65% year-over-year to $261000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (up 1129.29% YoY) and the FY2025 annual result came in at -$1.1 million, down 254.75% from the prior year.
- Change in Accured Expenses was $261000.0 for Q1 2026 at Achieve Life Sciences, up from -$510000.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $2.7 million in Q2 2025 and bottomed at -$2.1 million in Q1 2025.
- A 5-year average of $14058.8 and a median of $261000.0 in 2026 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2024 — Change in Accured Expenses soared 576.27% — and 2025, when it slumped 542.7%.
- Achieve Life Sciences' Change in Accured Expenses stood at $287000.0 in 2022, then rose by 12.54% to $323000.0 in 2023, then tumbled by 47.68% to $169000.0 in 2024, then sank by 401.78% to -$510000.0 in 2025, then soared by 151.18% to $261000.0 in 2026.
- Business Quant data shows ACHV's Change in Accured Expenses at $261000.0 in Q1 2026, -$510000.0 in Q4 2025, and -$1.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | 931,000.00 |
| 4 | BeOne Medicines | 472.04 Bn | 467.25 Bn | 1.35 Bn | -16.82 Mn |
| 5 | Vertex Pharmaceuticals | 122.28 Bn | 115.03 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 70.07 Bn | 61.31 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 56.16 Bn | 50.98 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.56 Bn | 34.55 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Achieve Life Sciences | 325.36 Mn | 325.36 Mn | - | 261,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 261,000.00 |
| Mar 31, 2026 | 261,000.00 |
| Dec 31, 2025 | -510,000.00 |
| Dec 31, 2025 | -510,000.00 |
| Sep 30, 2025 | -1.24 Mn |
| Sep 30, 2025 | -1.24 Mn |
| Jun 30, 2025 | 2.71 Mn |
| Jun 30, 2025 | 2.71 Mn |
| Mar 31, 2025 | -2.06 Mn |
| Mar 31, 2025 | -2.06 Mn |
| Dec 31, 2024 | 169,000.00 |
| Dec 31, 2024 | 169,000.00 |
| Sep 30, 2024 | 281,000.00 |
| Sep 30, 2024 | 281,000.00 |
| Jun 30, 2024 | 1.71 Mn |
| Jun 30, 2024 | 1.71 Mn |
| Mar 31, 2024 | -1.45 Mn |
| Mar 31, 2024 | -1.45 Mn |
| Dec 31, 2023 | 323,000.00 |
| Dec 31, 2023 | 323,000.00 |